Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.62
    +0.14 (+0.18%)
     

  • GOLD FUTURES

    2,322.40
    -8.80 (-0.38%)
     

  • DOW

    38,863.04
    +10.77 (+0.03%)
     

  • Bitcoin GBP

    50,525.29
    -38.86 (-0.08%)
     

  • CMC Crypto 200

    1,311.61
    -53.51 (-3.92%)
     

  • NASDAQ Composite

    16,319.87
    -29.38 (-0.18%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Company News For Nov 26, 2019

Zacks Equity Research

  • Shares of Aquestive Therapeutics, Inc. AQST gained 17.3% after the specialty pharmaceutical company received the FDA approval for EXSERVAN for the treatment of amyotrphic lateral sclerosis.

  • Shares of Intercept Pharmaceuticals, Inc. ICPT rose 8.4% after the FDA accepted Intercept’s New Drug Application for obeticholic acid for the treatment of Liver Fibrosis.

  • Shares of CymaBay Therapeutics, Inc. CBAY declined 76% after the clinical-stage biopharmaceutical company halted the clinical development of Seladelpar.

  • Shares of Surface Oncology, Inc. SURF lost 21% after clinical-stage immuno-oncology company reported a $25 million debt financing from K2 HealthVentures.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intercept Pharmaceuticals, Inc. (ICPT) : Free Stock Analysis Report
 
CymaBay Therapeutics Inc. (CBAY) : Free Stock Analysis Report
 
Surface Oncology, Inc. (SURF) : Free Stock Analysis Report
 
Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research